Viking Therapeutics, Inc. (VKTX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
VKTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Viking Therapeutics, Inc. (VKTX) trades at a price-to-earnings ratio of -10.1x, with a stock price of $32.28 and trailing twelve-month earnings per share of $-4.09.
Compared to the Healthcare sector median P/E of 22.1x, VKTX trades at a 146% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, VKTX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VKTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VKTX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $203B | 12.7Lowest | 0.61Best | +2% | |
| $933B | 43.0 | 1.49 | +96%Best | |
| $179B | 23.3 | 7.91 | +88% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See VKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VKTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VKTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVKTX — Frequently Asked Questions
Quick answers to the most common questions about buying VKTX stock.
Is VKTX stock overvalued or undervalued?
VKTX current P/E: -10.1x. 5-year average P/E: N/A. Percentile: N/A.
How does VKTX's valuation compare to peers?
Viking Therapeutics, Inc. P/E of -10.1x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is VKTX's PEG ratio?
VKTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.